ORYZON Announces Encouraging Top-line Results from Phase I-IIA Clinical Trial in Acute Leukemia of RG6016 (ORY-1001) at the American Society of Hematology 2016 Annual Meeting
BARCELONA, SPAIN and CAMBRIDGE MA.
Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced yesterday encouraging topline results from the First in Man international multicenter Phase I clinical trial with RG6016 (a potent and selective inhibitor of lysine-specific histone demethylase-1, previously known as ORY-1001) in relapsed or refractory acute leukemia (RR-AL) patients (EUDRACT nº 2013-002447-29). Results were presented in a poster session at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego, California.